E-LIB Suche - Ergebnisse für: Sessa, C.

1

Challenges in oncology career: are we closing the gender ga..:

Linardou, H. ; Adjei, A.A. ; Bajpai, J....
ESMO Open. 8 (2023) 2 - p. 100781 , 2023

Link: https://doi.org/10.1016/..

2

INOVATYON/ ENGOT-ov5 study: Randomized phase III internatio..:

Colombo, N. ; Gadducci, A. ; Sehouli, J....
British Journal of Cancer. 128 (2023) 8 - p. 1503-1513 , 2023

Link: https://doi.org/10.1038/..

3

50P Can we learn from failures? A systematic review and met..:

Martorana, F. ; Sessa, C. ; Lheureux, S..
ESMO Open. 8 (2023) 1 - p. 100830 , 2023

Link: https://doi.org/10.1016/..

4

Capability of Far-Infrared for the selective identification..:

Giménez, P. ; Linares, A. ; Sessa, C...
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 266 (2022) - p. 120411 , 2022

Link: https://doi.org/10.1016/..

5

The impact of COVID-19 on cancer care and oncology clinical..:

Sessa, C. ; Cortes, J. ; Conte, P....
ESMO Open. 7 (2022) 1 - p. 100339 , 2022

Link: https://doi.org/10.1016/..

6

Has COVID-19 had a greater impact on female than male oncol..:

Garrido, P. ; Adjei, A.A. ; Bajpai, J....
ESMO Open. 6 (2021) 3 - p. 100131 , 2021

Link: https://doi.org/10.1016/..

7

Clinical benefit of systemic therapies for recurrent ovaria..:

Broekman, K.E. ; van Kruchten, M. ; van Tinteren, H....
ESMO Open. 6 (2021) 4 - p. 100229 , 2021

Link: https://doi.org/10.1016/..

8

Female leadership in oncology—has progress stalled? Data fr..:

Berghoff, A.S. ; Sessa, C. ; Yang, J.C.-H....
ESMO Open. 6 (2021) 6 - p. 100281 , 2021

Link: https://doi.org/10.1016/..

9

Avelumab alone or in combination with pegylated liposomal d..:

Pujade-Lauraine, E. ; Fujiwara, K. ; Ledermann, J.A....
Gynecologic Oncology. 154 (2019) - p. 21-22 , 2019

Link: https://doi.org/10.1016/..

10

Clinical benefit of controversial first line systemic thera..:

Broekman, K.E. ; Jalving, M. ; van Tinteren, H...
Cancer Treatment Reviews. 69 (2018) - p. 233-242 , 2018

Link: https://doi.org/10.1016/..

11

Phase I study of lurbinectedin (PM01183) in combination wit..:

Forster, M. ; Sessa, C. ; Von Moos, R....
European Journal of Cancer. 72 (2017) - p. S134 , 2017

Link: https://doi.org/10.1016/..

12

Phase I trial of the oral smoothened inhibitor sonidegib in..:

Stathis, A. ; Hess, D. ; von Moos, R....
Investigational New Drugs. 35 (2017) 6 - p. 766-772 , 2017

Link: https://doi.org/10.1007/..

13

A phase I study of PankoMab-GEX, a humanised glyco-optimise..:

Fiedler, W. ; DeDosso, S. ; Cresta, S....
European Journal of Cancer. 63 (2016) - p. 55-63 , 2016

Link: https://doi.org/10.1016/..

14

Genetic susceptibility to cutaneous melanoma in southern Sw..:

Mangas, C. ; Potrony, M. ; Mainetti, C....
British Journal of Dermatology. 175 (2016) 5 - p. 1030-1037 , 2016

Link: https://doi.org/10.1111/..

15

Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 ..:

Aoyama, T. ; Fasolo, A. ; Stathis, A....
European Journal of Cancer. 69 (2016) - p. S117-S118 , 2016

Link: https://doi.org/10.1016/..